



ASX RELEASE (21 OCTOBER 2019)

## THC Global Builds New Zealand CBD Presence

### Key Points:

- THC Global continues exclusive distribution of Endoca CBD products in New Zealand with shipment of products recently landed
- Regulations in New Zealand enable straight forward prescription process with broader patient accessibility than in Australia
- Over 100 healthcare professionals enrolled on a THC Global supported information portal for prescribers in New Zealand – CBDinfo.co.nz
- Established supply pathway under New Zealand regulations which will be used for supply of THC Global's Australian produced medicinal cannabis next year

**THC Global Group Limited (THC Global or the Company)** (ASX:THC) is pleased to provide an update on the Company's activities in New Zealand, focused on the provision of cannabidiol (**CBD**) products to patients in New Zealand under its exclusive distributor agreement with Endoca.

Access to CBD products in New Zealand is relatively straightforward, with patients able to seek a prescription for CBD products just as they can for any other prescription medicine without the need for government approvals on a case-by-case basis as was previously required. As a result, New Zealand has, proportionally, a far larger immediately accessible patient population compared to Australia given the regulatory hurdles for supply of medicinal cannabis to patients in Australia.

In order to provide prescribers with the best available information on CBD products to assist in making decisions on prescribing them to patients, THC Global provided financial assistance to DATAPHARM, a healthcare company in New Zealand, to launch CBDinfo.co.nz (**CBDinfo**). CBDinfo is a platform providing medical practitioners relevant and evidenced information about the use, availability, and potential benefits and risks of using CBD products. To access the "For Practitioners" section, medical practitioners are required to enrol onto the platform. Since launch in June 2019, over 100 medical practitioners have enrolled. Once enrolled, practitioners can access detailed information on efficacy and safety data, as well as details on how to prescribe CBD products.

THC Global is committed to providing New Zealand prescribers access to high quality information and guidance on CBD and has funded and participated in a number of prescriber engagement and education events in New Zealand, driving awareness of the accessibility of CBD products such as the Endoca CBD products supplied by THC Global.

THC Global's import and distribution process makes Endoca products available to all wholesalers in New Zealand, rather than a specialised subset or specific region. Initial sales levels have been positive, supporting THC Global's focus on doctor education and information provision as a means of responsibly supporting medical professionals and patients in the use of CBD.

The supply pathways and prescriber engagement and education activities THC Global has developed with the distribution of the Endoca product range will allow for THC Global to enter the New Zealand market with its own Australian produced medicine range next year. THC Global's medicine range for export next year will be pharmaceutical Good Manufacturing Practice (**GMP**) certified medicines produced from its Southport Manufacturing Facility.



**For further information, please contact:**



**Ken Charteris**  
Chief Executive Officer  
e: [ceo@thc.global](mailto:ceo@thc.global)

**Henry Kinstlinger**  
Company Secretary  
e: [corporate@thc.global](mailto:corporate@thc.global)  
p: +61 2 8644 0601

**Sonny Didugu**  
Investors & Media  
e: [media@thc.global](mailto:media@thc.global)  
p: +61 2 8088 4760

**THC Global Group Limited (ASX: THC) [thc.global](http://thc.global)**

THC Global operates under a 'Farm to Pharma' pharmaceutical model, now holding all three key cannabis licences being a Cannabis Research Licence, a Medicinal Cannabis Licence (Cultivation), and two Manufacture Licences through its domestic medicinal cannabis subsidiaries THC Pharma and Canndeo. THC Global has secured a significant cannabis growing capacity over multiple cultivation projects. and owns a licenced GMP ready high-volume bio-pharma extraction facility with attached testing and product development laboratory.

THC Global is in prime position to commence medicinal cannabis production to service both domestic patients and the global export market. THC Global is active globally with operations in Australia, New Zealand, and Canada and partnerships across Europe, Asia, and the Middle East. In addition to its core Australian medicinal cannabis assets, THC Global has a significant Canadian presence – both in cannabis and in hydroponics equipment. THC Global's Canadian cannabis operation, Canndeo Canada (formerly, Vertical Canna), holds property in Nova Scotia, Canada being developed into a large scale cannabis production site. THC Global's hydroponics equipment division, Crystal Mountain, is a revenue generating manufacturer, wholesaler, and retailer of hydroponics equipment and supplies for cannabis cultivation.